LSTA vs. ALGS, TNYA, LPTX, XBIT, ATOS, ANRO, IVA, NVCT, DBVT, and INZY
Should you be buying Lisata Therapeutics stock or one of its competitors? The main competitors of Lisata Therapeutics include Aligos Therapeutics (ALGS), Tenaya Therapeutics (TNYA), Leap Therapeutics (LPTX), XBiotech (XBIT), Atossa Therapeutics (ATOS), Alto Neuroscience (ANRO), Inventiva (IVA), Nuvectis Pharma (NVCT), DBV Technologies (DBVT), and Inozyme Pharma (INZY). These companies are all part of the "pharmaceutical products" industry.
Lisata Therapeutics vs.
Lisata Therapeutics (NASDAQ:LSTA) and Aligos Therapeutics (NASDAQ:ALGS) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, dividends, community ranking, profitability, valuation, institutional ownership, risk, earnings and analyst recommendations.
In the previous week, Lisata Therapeutics had 1 more articles in the media than Aligos Therapeutics. MarketBeat recorded 2 mentions for Lisata Therapeutics and 1 mentions for Aligos Therapeutics. Aligos Therapeutics' average media sentiment score of 1.94 beat Lisata Therapeutics' score of 0.00 indicating that Aligos Therapeutics is being referred to more favorably in the news media.
Lisata Therapeutics has higher earnings, but lower revenue than Aligos Therapeutics. Aligos Therapeutics is trading at a lower price-to-earnings ratio than Lisata Therapeutics, indicating that it is currently the more affordable of the two stocks.
8.9% of Lisata Therapeutics shares are owned by institutional investors. Comparatively, 60.4% of Aligos Therapeutics shares are owned by institutional investors. 9.1% of Lisata Therapeutics shares are owned by insiders. Comparatively, 8.8% of Aligos Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Aligos Therapeutics received 13 more outperform votes than Lisata Therapeutics when rated by MarketBeat users. However, 93.33% of users gave Lisata Therapeutics an outperform vote while only 65.85% of users gave Aligos Therapeutics an outperform vote.
Lisata Therapeutics presently has a consensus target price of $15.00, indicating a potential upside of 284.62%. Aligos Therapeutics has a consensus target price of $75.00, indicating a potential upside of 121.96%. Given Lisata Therapeutics' higher possible upside, equities research analysts clearly believe Lisata Therapeutics is more favorable than Aligos Therapeutics.
Lisata Therapeutics has a beta of 1.14, suggesting that its stock price is 14% more volatile than the S&P 500. Comparatively, Aligos Therapeutics has a beta of 2.5, suggesting that its stock price is 150% more volatile than the S&P 500.
Lisata Therapeutics has a net margin of 0.00% compared to Aligos Therapeutics' net margin of -1,283.19%. Lisata Therapeutics' return on equity of -51.19% beat Aligos Therapeutics' return on equity.
Summary
Lisata Therapeutics beats Aligos Therapeutics on 10 of the 15 factors compared between the two stocks.
Get Lisata Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for LSTA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Lisata Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:LSTA) was last updated on 1/21/2025 by MarketBeat.com Staff
Free LSTA Stock Alerts